-
Prosperity Pharmaceutical's IPO, how will CXO play in the second half?
Time of Update: 2022-10-25
"Chen Ping, Chairman of Prosperity Pharmaceutical: Focus on Science and Innovation, Build a Technology "Moat", China Securities News, 2022-10-11 Founded in 2007, Prosperity Pharma is a one-stop integrated service provider for the R&D and commercial production of small molecule new drugs, with its main business covering drug discovery, process research and development, and commercial manufacturing.
-
Recently, a large number of pharmaceutical companies have announced the suspension and termination of new drug research and development
Time of Update: 2022-10-25
It is understood that a number of pharmaceutical companies have recently announced the suspension or termination of the development of new drugs.
It is understood that a number of pharmaceutical companies have recently announced the suspension or termination of the development of new drugs.
-
$1.76 billion! Jazz Pharmaceuticals introduces a HER2 bispecific antibody and BeiGene has rights in the Asia Pacific region
Time of Update: 2022-10-25
” Kenneth Galbraith, Chairman and CEO of Zymeworks, said: Zanidatamab, a HER2-targeted, bispecific antibody with a novel mechanism of action, has shown convincing antitumor activity in several HER2-expressing cancers, both as monotherapy and in combination with chemotherapy and other drugs.
-
This drug may become the next outlet, and a large number of domestic pharmaceutical companies rush to the beach
Time of Update: 2022-10-25
【Pharmaceutical Network Market Analysis】 News on October 21, the pharmaceutical and biological sector of Hong Kong stocks rose, of which Akeso Biotech rose by more than 8%. In the past 6 trading days,
-
Chen Shuqing interview 8,000 words, take you to understand "tumor therapeutic vaccine"
Time of Update: 2022-10-25
On the other hand, neoantigens are not only therapeutic targets for tumors, but also targets for other refractory diseases, such as diabetes, atherosclerosis, and Alzheimer's disease Professor Chen Shuqing: Overall, although no new tumor therapeutic vaccines have been approved for marketing at home and abroad in the past ten years, the development of foreign tumor therapeutic vaccines is ahead of China in terms of quantity and clinical trial progress.
-
Under the normalization of centralized procurement of proprietary Chinese medicines, the transformation and upgrading of traditional Chinese medicine enterprises is imminent
Time of Update: 2022-10-25
In addition to innovation, before the launch of national centralized procurement of proprietary Chinese medicines, in fact, many enterprises are still carrying out the layout of the entire industrial chain and actively launching mergers and reorganizations.
-
Sullivan: Capital continues to pour in to promote the development of the rare disease industry, and more patients with rare diseases will benefit from it
Time of Update: 2022-10-25
Sullivan insight Recently, Alexion Pharmaceuticals (hereinafter referred to as "Alexion Pharmaceuticals"), a subsidiary of AstraZeneca's rare disease business, announced the acquisition of LogicBio Therapeutics, a clinical-stage genetic company, for US$68 million (approximately RMB484 million).
-
With a drug market of more than $20 billion, a large number of domestic pharmaceutical companies are making efforts
Time of Update: 2022-10-25
On the whole, in addition to the commonly used TNF-α antagonist adalimumab, three imported IL-17(R) target monoclonal antibody injection drugs have been approved for marketing in China.
-
$255 million! AbbVie acquires DJS Abodies
Time of Update: 2022-10-25
£6 million in funding announced in 2020 Dr. Jonathon Sedgwick, vice president and head of global discovery research at AbbVie, said, "We are delighted to bring the innovative science behind DJS-002 and the talented team of DJS to AbbVie. The acquisition will provide new capabilities to strengthen our current antibody research activities, provide opportunities to strengthen our immunology portfolio and provide a solid foothold for expanded research efforts at the Dynamic Biosciences Centre in Oxford, UK.
-
A picture reviews the price reduction of domestic PD-1 medical insurance negotiations! "New and old players" in 2022 "roll" together?
Time of Update: 2022-10-25
NSCLC: non-squamous non-small cell lung cancer; HCC: hepatocellular carcinoma; r/r: relapsed/refractory Red letter: Early renewal; Blue words: normal renewal; Blue background: Previously included in the medical insurance catalog Among them, Innovent Biologics Daboshu is the first normal renewal and adds 3 new indications; BeiGene and Junshi Biotech renewed their contracts one year ahead of schedule, with 3 and 2 indications, respectively; Hengrui Pharmaceutical Erica has previously been covered by 4 indications.
-
$610 million! Lilly acquires Akouos, a gene therapy company
Time of Update: 2022-10-25
Original English text: On October 18, Eli Lilly announced the acquisition of gene therapy company Akouos, Inc.
Original English text: On October 18, Eli Lilly announced the acquisition of gene therapy company Akouos, Inc.
-
The National Health Insurance Administration made a statement! The four types of drugs and devices will not be collected for the time being
Time of Update: 2022-10-25
Recently, the official website of the National Medical Insurance Bureau published a large number of replies to the proposals and suggestions of deputies to the National People's Congress and members
-
The wave of financing in the pharmaceutical field is still continuing, and the financing amount exceeding 100 million yuan has become the norm
Time of Update: 2022-10-25
, an innovative company in the field of neuromodulation in China, announced (hereinafter referred to as "Shenwok Medical") that it has successfully completed nearly 100 million yuan of Series B financing.
-
In-depth India's "World Pharmacy" Path
Time of Update: 2022-10-25
The global biomedical industry is showing a trend of agglomeration development, with developed countries and regions represented by the United States and Europe dominating, and emerging economies rep
-
How can China's innovative drugs solve the problem of going global?
Time of Update: 2022-10-25
On October 14th, five industry experts from Northscope were invited in the live broadcast room: Dr. Chen Gang, Chief Scientific Officer of Northscope, Professor Hu Bei, Chief Clinical Pharmacology Scientist of Northscope, Dr. He Kun, Chief Statistician of Northscope, Mr. Li Jigang, Chief Medical Officer of Northscope, and Mr. Wang Tao, Senior Vice President of Northscope, around the theme of "how to maximize the clinical value of innovative drugs and international opportunities", to bring you wonderful analysis and discussion.
-
After local pharmaceutical companies laid off their U.S. R&D teams, he is considering returning to MNC or returning to China. The internationalization of innovative drugs is still "paying tuition"...
Time of Update: 2022-10-25
After wave of practice, the industry has begun to realize whether pharmaceutical companies have accumulated funds, provoked tens of millions of dollars in international multi-center clinical research expenses for foreign clinics, whether they have localized teams, understand the rules of the game in various countries, and whether they have a differentiated product foundation that can meet uncovered clinical needs and have promotion value.
-
Under the adjustment of the medical insurance catalogue, these two major drug markets will usher in new development opportunities
Time of Update: 2022-10-25
Among them, there is no time limit for "approval for marketing after January 1, 2017" for the declaration conditions for rare disease drugs, and drugs included in the national list of encouraged generic drugs and encouraged research and development to apply for children's drugs can be declared in this year's medical insurance catalogue.
-
Are pharmaceutical stocks real this time?
Time of Update: 2022-10-25
After that, the previous midstream research and development phased results have boosted the market of upstream APIs. In the end, the epidemic has given the pharmaceutical and biotechnology sector more imagination, but the return cycle of the industry cannot meet market expectations, resulting in frequent sector rotation.
-
The eighth batch of collective procurement is like an arrow, which drugs are expected to be "collected"?
Time of Update: 2022-10-25
The industry believes that the reply letter of the National Medical Insurance Bureau means that the promotion of centralized procurement of biological drugs may have entered the agenda, and the market pattern of tens of billions of biosimilars will usher in changes in the future.
-
The HER2 ADC vent came, but it didn't
Time of Update: 2022-10-25
According to the phase I clinical data in China led by Xinma Biologics, a subsidiary of Zhejiang Pharmaceutical, a partner of Ambrx, ARX788 has an objective response rate of 66% in patients who are resistant or refractory to previous HER2 treatment.
